Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds

New insights into the treatment of ALS: clinical trial results led by Brighton and Sussex Medical School published

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet. This is the first study to investigate the effectiveness and safety of low-dose interleukin-2 (IL2LD) for amyotrophic lateral sclerosis (ALS), also known as Motor Neurone Disease (MND).

Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and extended the lifespan of people with this degenerative disorder.

Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025

Neurodegenerative diseases like ALS, frontotemporal dementia, and Friedreich’s ataxia pose significant challenges with limited treatment options. ALS and frontotemporal dementia lead to motor neuron degeneration … Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025 Read More » The post Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025 first appeared on GeneOnline News. The post Neurodegener…

Neurosense, awaiting Canada approval, scales PrimeC production

Neurosense Therapeutics said it’s scaled production of PrimeC, its oral therapy for amyotrophic lateral sclerosis (ALS), to commercial levels as it awaits regulatory approval to launch the medication in Canada. “This manufacturing milestone represents a critical leap forward in our commercialization roadmap,” Alon Ben-Noon, CEO of Neurosense, said in a company press release. Based on results from the Phase 2b PARADIGM trial (NCT05357950), the co…

Revolutionary Sugar-Coated Nanotherapy Significantly Enhances Neuron

Scientists at Northwestern University have achieved a significant breakthrough in the fight against neurodegenerative diseases, specifically targeting conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). These illnesses are notorious for their devastating impact, characterized by the misfolding and aggregation of proteins around neurons, ultimately leading to cell death. In response to this alarming issue, the research…

Low-dose interleukin-2 found safe and effective for slowing motor neurone disease progression

A major clinical trial has found that low-dose interleukin-2 (IL2LD) is safe and may significantly extend survival in people with motor neurone disease (ALS) Motor neurone disease affects around 45,000 people in Europe and attacks the nerves that control movement (motor nerves), so muscles no longer work. Around a quarter of people with the disease die within a year of developing symptoms, and more than half within two to three years of diagnosi…